Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
暂无分享,去创建一个
[1] D. Lodge,et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.
[2] R. Kerwin,et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. , 2000, The British journal of psychiatry : the journal of mental science.
[3] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[4] C. Marsden,et al. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. , 1980, European journal of pharmacology.
[5] Ravi S. Menon,et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.
[6] K. Erlandsson,et al. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride , 2005, Psychopharmacology.
[7] T. Crow,et al. CEREBRAL VENTRICULAR SIZE AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA , 1976, The Lancet.
[8] Karin E. Borgmann-Winter,et al. Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.
[9] E. Kandel,et al. Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[10] H. Moore,et al. Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[11] R. Roth,et al. The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.
[12] A. Belger,et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.
[13] Paul J. Harrison. The neuropathology of schizophrenia , 2008 .
[14] P. Calabresi,et al. Endogenous ACh enhances striatal NMDA‐responses via M1‐like muscarinic receptors and PKC activation , 1998, The European journal of neuroscience.
[15] M. Boekel,et al. Kinetic modelling , 2022 .
[16] K. Jellinger,et al. DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS , 1980, The Lancet.
[17] H. Lehmann,et al. Observations on the Action of Sernyl — A New Psychotropic Drug , 1961, Canadian Psychiatric Association journal.
[18] John H. Gilmore,et al. Apoptotic mechanisms and the synaptic pathology of schizophrenia , 2006, Schizophrenia Research.
[19] L. Mallet,et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia , 2001, British Journal of Psychiatry.
[20] Alan A. Wilson,et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. , 2004, The American journal of psychiatry.
[21] J. Libiger,et al. Antiepileptic drugs in schizophrenia: a review , 2002, European Psychiatry.
[22] Kevin T. Hansen,et al. Dopamine D2 densities and the schizophrenic brain , 1998, Schizophrenia Research.
[23] D. Malone,et al. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. , 1984, Journal of toxicology. Clinical toxicology.
[24] J. Krystal,et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.
[25] R. Murray,et al. D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.
[26] R. Rosenheck,et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1999, The American journal of psychiatry.
[27] J. Newcomer,et al. NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.
[28] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.
[30] Yasuhiro Kaneda,et al. Serotonin receptors : their key role in drugs to treat schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[31] S. Grimwood,et al. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. , 2000, European journal of pharmacology.
[32] R. Tandon. Cholinergic aspects of schizophrenia , 1999, British Journal of Psychiatry.
[33] S. Stone-Elander,et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.
[34] D Hell,et al. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.
[35] H. Beech,et al. The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers. , 1960, The Journal of mental science.
[36] C. Bakker,et al. Observations on the psychotomimetic effects of Sernyl. , 1961, Comprehensive psychiatry.
[37] H. Tanila,et al. Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man , 2005, Psychopharmacology.
[38] S. Snyder,et al. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. , 1976, Molecular pharmacology.
[39] M. Laruelle. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[40] S. Kapur,et al. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia , 2002, Molecular Psychiatry.
[41] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[42] P Riederer,et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. , 1984, Science.
[43] L. Siever,et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide , 2004, Biological Psychiatry.
[44] P. Kalus,et al. The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients , 2000, Neuroreport.
[45] D. Doudet,et al. 6-18F-DOPA PET study in patients with schizophrenia , 2000, Psychiatry Research: Neuroimaging.
[46] R. Conley,et al. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. , 2000, The American journal of psychiatry.
[47] A. Becker,et al. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia , 2004, Neuroscience.
[48] P. Somogyi,et al. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons , 1995, Nature.
[49] B. Lipska. CRSN Symposium: Focus on Schizophrenia Symposium du CRSN : le point sur la schizophrénie Using animal models to test a neurodevelopmental hypothesis of schizophrenia , 2004 .
[50] Roger N Gunn,et al. A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. , 2004, Nuclear medicine and biology.
[51] Eve C. Johnstone,et al. Grey matter changes over time in high risk subjects developing schizophrenia , 2005, NeuroImage.
[52] Philip Seeman,et al. Atypical Antipsychotics: Mechanism of Action , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[53] G. Rosoklija,et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. , 2000, Archives of general psychiatry.
[54] J. Gold,et al. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome , 1998, International clinical psychopharmacology.
[55] Peter J Ell,et al. Limbic selectivity of clozapine , 1997, The Lancet.
[56] D. Javitt. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients , 2006, Current opinion in psychiatry.
[57] L. DeLisi,et al. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia , 2005, Schizophrenia Research.
[58] C. Reutelingsperger,et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] Hideo Tsukada,et al. Chronic NMDA Antagonism Impairs Working Memory, Decreases Extracellular Dopamine, and Increases D1 Receptor Binding in Prefrontal Cortex of Conscious Monkeys , 2005, Neuropsychopharmacology.
[60] R. McCarley,et al. A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.
[61] J. Lieberman,et al. Apoptotic mechanisms in the pathophysiology of schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[62] H. Meltzer,et al. N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors , 2005, Neuropsychopharmacology.
[63] A. Guidotti,et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon , 2005, Psychopharmacology.
[64] Marc Ansseau,et al. Dopamine–glutamate reciprocal modulation of release and motor responses in the rat caudate–putamen and nucleus accumbens of “intact” animals , 2005, Brain Research Reviews.
[65] M Laruelle,et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.
[66] J. Meador-Woodruff,et al. Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.
[67] B. Moghaddam,et al. Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.
[68] R. Gunn,et al. Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor. , 2003, Nuclear medicine and biology.
[69] Sooyoung Chung,et al. Maternal Stress Produces Learning Deficits Associated with Impairment of NMDA Receptor-Mediated Synaptic Plasticity , 2006, The Journal of Neuroscience.
[70] J. Olney,et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.
[71] R. Murray,et al. Is schizophrenia a neurodevelopmental disorder? , 1987, British medical journal.
[72] B. Mazoyer,et al. The Estimated Density of D2 Striatal Receptors in Schizophrenia , 1991, British Journal of Psychiatry.
[73] P. Seeman,et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[74] N. Uranova,et al. Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study , 2005, Synapse.
[75] R. Parsey,et al. Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression , 2001, Biological Psychiatry.
[76] J. Lauriello,et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.
[77] Philip Seeman,et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[78] N. Volkow,et al. Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.
[79] M. Laruelle,et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.
[80] S. Haber,et al. The interface between dopamine neurons and the amygdala: implications for schizophrenia. , 1997, Schizophrenia bulletin.
[81] D. Goff,et al. Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.
[82] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[83] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[84] B. Morris,et al. Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs , 2003, Neuropsychopharmacology.
[85] J. Deakin,et al. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses , 2001, Neuroreport.
[86] B. Pakkenberg,et al. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics , 1992, Schizophrenia Research.
[87] S. Siris,et al. Implications of normal brain development for the pathogenesis of schizophrenia. , 1988, Archives of general psychiatry.
[88] M. Poulter,et al. INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA , 1978, The Lancet.
[89] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[90] R. Mckernan,et al. Generation and Characterisation of Stable Cell Lines Expressing Recombinant Human N‐Methyl‐d‐Aspartate Receptor Subtypes , 1996, Journal of neurochemistry.
[91] Hans-Georg Buchholz,et al. The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia , 2006, Neuropsychopharmacology.
[92] R. Behrendt. Dysregulation of thalamic sensory ‘transmission’ in schizophrenia: neurochemical vulnerability to hallucinations , 2006, Journal of psychopharmacology.
[93] L. Iversen,et al. Dopaminergic abnormalities in postmortem schizophrenic brain. , 1980, Advances in biochemical psychopharmacology.
[94] G. Reynolds,et al. Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models. , 2004, Neurotoxicity research.
[95] Gähwiler. Alterations in dendritic morphology induced by lesions, chemical deafferentation and epileptiform activity. , 1999, Acta physiologica Scandinavica.
[96] G. Reynolds,et al. Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models , 2009, Neurotoxicity Research.
[97] Douglas W. Jones,et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. , 2003, The American journal of psychiatry.
[98] D. Lewis,et al. Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.
[99] R. Tandon,et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication , 1993, Biological Psychiatry.
[100] N. Andreasen. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. , 1999, Archives of general psychiatry.
[101] K. Erlandsson,et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.
[102] J. Tiihonen,et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. , 2005, The Journal of clinical psychiatry.
[103] Myriam Bernaudin,et al. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? , 2001, Trends in Neurosciences.
[104] S. Leucht,et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.
[105] J. Hietala,et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.
[106] S. Deutsch,et al. Topiramate antagonizes MK-801 in an animal model of schizophrenia. , 2002, European journal of pharmacology.
[107] R Kono,et al. Antibody titres to enterovirus type 70 in the 1981 Indian epidemic of acute haemorrhagic conjunctivitis. , 1981, Lancet.
[108] A. Levey,et al. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[109] C. Hanstock,et al. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. , 2004, The American journal of psychiatry.
[110] John Suckling,et al. For personal use. Only reproduce with permission from The Lancet Publishing Group. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy , 2002 .
[111] T. Sejnowski,et al. Simulations of cortical pyramidal neurons synchronized by inhibitory interneurons. , 1991, Journal of neurophysiology.
[112] N. Craddock,et al. The genetics of schizophrenia and bipolar disorder: dissecting psychosis , 2005, Journal of Medical Genetics.
[113] Tao Li,et al. The genetics of schizophrenia: glutamate not dopamine? , 2003, European journal of pharmacology.
[114] Paul J. Harrison,et al. Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond , 2006, Biological Psychiatry.
[115] J. Tiihonen,et al. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.
[116] B. Yamamoto,et al. Dopaminergic and GABAergic modulation of glutamate release from rat subthalamic nucleus efferents to the substantia nigra , 2006, Brain Research.
[117] S. Gacinovic,et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study , 2000, Psychopharmacology.
[118] D J Healy,et al. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. , 2000, The American journal of psychiatry.
[119] D. Javitt. Management of negative symptoms of schizophrenia , 2001, Current psychiatry reports.
[120] J. Lieberman,et al. Cognitive Development in Schizophrenia: Follow-Back from the First Episode , 2006, Journal of clinical and experimental neuropsychology.
[121] K. Berridge,et al. The neural basis of drug craving: An incentive-sensitization theory of addiction , 1993, Brain Research Reviews.
[122] B. Bogerts,et al. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons , 1998, Psychiatry Research: Neuroimaging.
[123] G. Reynolds,et al. Neuronal calcium-binding proteins and schizophrenia , 2002, Schizophrenia Research.
[124] F. Benes,et al. Emerging principles of altered neural circuitry in schizophrenia , 2000, Brain Research Reviews.
[125] J. Krystal,et al. Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo , 2005, Biological Psychiatry.
[126] K. Erlandsson,et al. Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. , 2006, Nuclear medicine and biology.
[127] Ravi S. Menon,et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.
[128] P. Jeffrey Conn,et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[129] P. Illés,et al. D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex , 2004, Neuroscience Letters.
[130] Eve C. Johnstone,et al. Voxel-based morphometry of patients with schizophrenia or bipolar disorder and their unaffected relatives , 2004, Biological Psychiatry.
[131] C. Ikonomidou,et al. Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[132] B. Dean,et al. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. , 1999, Life sciences.
[133] Jürgen Gallinat,et al. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla , 2004, NeuroImage.
[134] Robin M. Murray,et al. Environmental risk factors for psychosis , 2005, Dialogues in clinical neuroscience.
[135] S. Sombati,et al. Cellular Actions of Topiramate: Blockade of Kainate‐Evoked Inward Currents in Cultured Hippocampal Neurons , 2000, Epilepsia.
[136] S. Kapur. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.
[137] Karl J. Friston,et al. Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.
[138] Paul J. Harrison,et al. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.
[139] Paul J. Harrison,et al. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.
[140] S. Ögren,et al. Phencyclidine- and Dizocilpine-Induced Hyperlocomotion Are Differentially Mediated , 1994, Neuropsychopharmacology.
[141] L. K. Srivastava,et al. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus , 2005, Neuroscience.
[142] U. Heresco-Levy. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[143] J. Meador-Woodruff,et al. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities , 2004, Schizophrenia Research.
[144] A. Giannini,et al. Acute ketamine intoxication treated by haloperidol: a preliminary study. , 2000, American journal of therapeutics.
[145] Akira Sawa,et al. Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.
[146] J. Seibyl,et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.
[147] B. Kolachana,et al. Catechol-O-Methyltransferase Genotype and Dopamine Regulation in the Human Brain , 2003, The Journal of Neuroscience.
[148] M. Giannini,et al. Comparison of Haloperidol and Chlorpromazine in the Treatment of Phencyclidine Psychosis , 1984, Journal of clinical pharmacology.
[149] L. Iversen,et al. DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS? , 1980, The Lancet.
[150] W T Carpenter,et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. , 1998, The American journal of psychiatry.
[151] R. Nussbaum,et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype , 2005, Nature Neuroscience.
[152] M. Egan,et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.
[153] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[154] Eve C Johnstone,et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia , 1999, The Lancet.
[155] A. Lawrence,et al. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.
[156] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[157] Daniel R. Weinberger,et al. Neuregulin 1 Transcripts Are Differentially Expressed in Schizophrenia and Regulated by 5′ SNPs Associated With the Disease , 2006 .
[158] S. Kapur,et al. Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[159] P. Seeman,et al. Dopamine agonist action of phencyclidine , 2005, Synapse.
[160] D. Lorrain,et al. Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 , 2003, Neuroscience.
[161] G. Rosenbaum,et al. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.
[162] D. Peters,et al. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. , 2006, CNS drug reviews.
[163] K. Erlandsson,et al. Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study , 2003, Journal of clinical psychopharmacology.
[164] G. Rosenbaum,et al. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. , 1962, Archives of general psychiatry.
[165] Franz X Vollenweider,et al. A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.
[166] J. Walecki,et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). , 2005, Pharmacopsychiatry.